

Current report № 209/27.10.2025

Dated 27.10.2025

Conclusion of a preliminary contract for the sale of a separate part of a commercial enterprise

Sofia, Bulgaria, October 27, 2025 – According to requirements on Art. 100t of the LPOS, **“Sopharma” AD** (SFA: Bulgarian stock exchange AD, SPH: Warsaw Stock Exchange) informs that following its strategy of focusing and optimization of its activities, the Company concluded preliminary contract for sale of a separate part from the commercial enterprise related to the production and trade of veterinary medicinal products and laboratory tests on food and biological products. As a result of the agreement no receivables or obligations arise for "Sopharma" AD as stipulated in Art. 114, para. 1, items 2 and 3 of the POSA. The contractual party is not a connected or related party as defined by the POSA. The Agreement defines the parameters and conditions, under performance on which can yes is attacks to deal by sale on the separate part from commercial enterprise of "Sopharma" AD. In accordance with the conditions in the agreement, the transfer of the separate part from a commercial enterprise of a public company can be carried out only after receiving an advance approval for execution on the transaction for sale on the separate part from a commercial enterprise, objectified in a decision of the general meeting of the shareholders of the public company.

An extraordinary general meeting of shareholders of “Sopharma” AD is to be convened, at which the proposal of the Board of Directors for a transaction to sell the separate part of the company's commercial enterprise related to the production and trade of veterinary medicinal products and laboratory testing of food and biological products will be submitted for voting. As an integral part of the materials for the EGMS invitation, a report under Art. 114a, para. 1 of the POSA will be presented, containing the legally required information in connection with the transaction proposed for approval.

Ognian Donev